Biological correlates of blood pressure variability in elderly at high risk of cardiovascular disease

American Journal of Hypertension

Volumn 28, Issue 4, 2015, Pages 469-479

  Poortvliet, Rosalinde K E ^a   Lloyd, Suzanne M ^b   Ford, Ian ^b   Sattar, Naveed ^c   De Craen, Anton J M ^a   Wijsman, Liselotte W ^a,d   Mooijaart, Simon P ^a,d,e   Westendorp, Rudi G J ^d   Jukema, J Wouter ^a   Ruijter, Wouter De ^a   Gussekloo, Jacobijn ^a   Stott, David J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Netherlands Consortium for Healthy Ageing   (Netherlands)

^e Institute for Evidence Based Medicine in Old Age   (Netherlands)

Author keywords

Blood pressure; cardiovascular risk; correlates; hypertension; mortality; old age; variability

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; AUTACOID; IL6 PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; AGE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; TIME;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; EUROPE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84952715389     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu181     Document Type: Article

References (42)

1. Cook NR, Rosner BA. Screening rules for determining blood pressure status in clinical trials. Application to the trials of hypertension prevention. Am J Epidemiol 1993; 137:1341-1352.
2. Klungel OH, de Boer A, Paes AH, Nagelkerke NJ, Seidell JC, Bakker A. Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. J Clin Epidemiol 2000; 53:1158-1163.
3. Klungel OH, de Boer A, Paes AH, Nagelkerke NJ, Seidell JC, Bakker A. Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension. Am J Hypertens 2000; 13:88-91.
4. Rosner B, Polk BF. The implications of blood pressure variability for clinical and screening purposes. J Chronic Dis 1979; 32:451-461.
5. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697-716.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
8. Howard SC, Rothwell PM. Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. Cerebrovasc Dis 2009; 28:331-340.
9. Muntner P, Joyce C, Levitan EB, Holt E, Shimbo D, Webber LS, Oparil S, Re R, Krousel-Wood M. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens 2011; 29:2332-2338.
10. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahl? B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895-905.
11. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011; 57:160-166.
12. Hata Y, Kimura Y, Muratani H, Fukiyama K, Kawano Y, Ashida T, Yokouchi M, Imai Y, Ozawa T, Fujii J, Omae T. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res 2000; 23:553-560.
13. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, Jaaskivi M, Nachev C, Parati G, O'Brien ET, Tuomilehto J, Webster J, Bulpitt CJ, Fagard RH; Syst-Eur Investigators. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21:2251-2257.
14. Geeganage C, Tracy M, England T, Sare G, Moulin T, Woimant F, Christensen H, De Deyn PP, Leys D, O'Neill D, Ringelstein EB, Bath PM; for TAIST Investigators. Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke 2011; 42:491-493.
15. Grove JS, Reed DM, Yano K, Hwang LJ. Variability in systolic blood pressure-a risk factor for coronary heart disease? Am J Epidemiol 1997; 145:771-776.
16. Poortvliet RK, Ford I, Lloyd SM, Sattar N, Mooijaart SP, de Craen AJ, Westendorp RG, Jukema JW, Packard CJ, Gussekloo J, de Ruijter W, Stott DJ. Blood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One 2012; 7:e52438.
17. Hsieh YT, Tu ST, Cho TJ, Chang SJ, Chen JF, Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5?5-year prospective analysis. Eur J Clin Invest 2012; 42:245-253.
18. Suchy-Dicey AM, Wallace ER, Mitchell SV, Aguilar M, Gottesman RF, Rice K, Kronmal R, Psaty BM, Longstreth WT Jr. Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. Am J Hypertens 2013; 26:1210-1217.
19. Sabayan B, Wijsman LW, Foster-Dingley JC, Stott DJ, Ford I, Buckley BM, Sattar N, Jukema JW, van Osch MJ, van der Grond J, van Buchem MA, Westendorp RG, de Craen AJ, Mooijaart SP. Association of visitto-visit variability in blood pressure with cognitive function in old age: prospective cohort study. BMJ 2013; 347:f4600.
20. Hata Y, Muratani H, Kimura Y, Fukiyama K, Kawano Y, Ashida T, Yokouchi M, Imai Y, Ozawa T, Fujii J, Omae T. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens 2002; 16:141-146.
21. Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol 2001; 38:427-437.
22. Diaz KM, Veerabhadrappa P, Kashem MA, Feairheller DL, Sturgeon KM, Williamson ST, Crabbe DL, Brown MD. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res 2012; 35:55-61.
23. Diaz KM, Veerabhadrappa P, Kashem MA, Thakkar SR, Feairheller DL, Sturgeon KM, Ling C, Williamson ST, Kretzschmar J, Lee H, Grimm H, Babbitt DM, Vin C, Fan X, Crabbe DL, Brown MD. Visit-to-visit and 24-h blood pressure variability: association with endothelial and smooth muscle function in African Americans. J Hum Hypertens 2013; 27:671-677.
24. Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol 2006; 21:486-491.
25. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, Prontera C, Emdin M, Flacco M, Schillaci G, DE Caterina R. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 2008; 31:2137-2146.
26. Kawai T, Ohishi M, Kamide K, Onishi M, Takeya Y, Tatara Y, Oguro R, Yamamoto K, Sugimoto K, Rakugi H. The impact of visit-to-visit variability in blood pressure on renal function. Hypertens Res 2012; 35:239-243.
27. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
28. Ford I, Blauw GJ, Murphy MB, Shepherd J, Cobbe SM, Bollen EL, Buckley BM, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane P, Norrie J, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ; The PROSPER Study Group. A prospective study of pravastatin in the elderly at risk (PROSPER): screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med 2002; 3:8.
29. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999; 84:1192-1197.
30. Sattar N, Murray HM, Welsh P, Blauw GJ, Buckley BM, Cobbe S, de Craen AJ, Lowe GD, Jukema JW, Macfarlane PW, Murphy MB, Stott DJ, Westendorp RG, Shepherd J, Ford I, Packard CJ; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6:e1000099.
31. Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J; PROSPER Study Group. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115:981-989.
32. Stott DJ, Robertson M, Rumley A, Welsh P, Sattar N, Packard CJ, Shepherd J, Trompet S, Westendorp RG, de Craen AJ, Jukema JW, Buckley B, Ford I, Lowe GD. Activation of hemostasis and decline in cognitive function in older people. Arterioscler Thromb Vasc Biol 2010; 30:605-611.
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
35. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938-948.
36. de Champlain J, Karas M, Toal C, Nadeau R, Larochelle P. Effects of antihypertensive therapies on the sympathetic nervous system. Can J Cardiol 1999; 15(Suppl A):8A-14A.
37. Eliasson M, Jansson JH, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension. A populationbased study in Sweden. J Hypertens 1997; 15:349-356.
38. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-1168.
39. Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T, Doba N. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998; 31:321-327.
40. Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, Schouten EG. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis risk in communities. Circulation 2000; 102:1239-1244.
41. Mooijaart SP, Sattar N, Trompet S, Lucke J, Stott DJ, Ford I, Jukema JW, Westendorp RG, de Craen AJ; PROSPER Study Group. Circulating interleukin-6 concentration and cognitive decline in old age: the PROSPER study. J Intern Med 2013; 274:77-85.
42. Mooijaart SP, Sattar N, Trompet S, Polisecki E, de Craen AJ, Schaefer EJ, Jahn SE, van Himbergen T, Welsh P, Ford I, Stott DJ, Westendorp RG; PROSPER Study Group. C-reactive protein and genetic variants and cognitive decline in old age: the PROSPER study. PLoS One 2011; 6:e23890.